Thrombolytic Therapy

This is a treatment that uses special medicines to break up blood clots. These clots can block blood flow, causing problems like heart attacks or strokes. The goal is to dissolve the clot and restore normal blood flow.

Therapy

What people using Thrombolytic Therapy report

Every report comes from a Lived member, sent anonymously.

Have you tried Thrombolytic Therapy for Ischemic Stroke?

NameHow it went

About Thrombolytic Therapy

How It Works

Thrombolytic therapy, often called thrombolysis or clot-busting treatment, uses medicines that dissolve a blood clot blocking an artery or vein. It is mainly an emergency treatment. When a clot cuts off blood flow to part of the brain (an ischemic stroke), to the heart muscle (a heart attack) or to the lungs (a pulmonary embolism), the tissue it supplies starts to be damaged. Brain cells begin to die within minutes, so reopening the vessel quickly can limit how much is lost. The main drugs are tissue plasminogen activators, often shortened to tPA, which switch on the body's own clot-dissolving process. In the US the two most used are alteplase (Activase) and tenecteplase (TNKase). The same effect that breaks down the harmful clot also weakens clots that protect against bleeding elsewhere in the body. That is the central trade-off: bleeding is the main risk, and the benefit shrinks the longer a clot has been in place.

Who It's For

Thrombolytic therapy is used for a small set of emergencies, and in each one the decision weighs how much there is to gain against the risk of bleeding. For an ischemic stroke, it can be given to adults whose stroke is caused by a clot, once a brain scan shows no bleeding. The US labels for both alteplase and tenecteplase call for treatment within 3 hours of symptoms starting, and stroke guidelines support treatment up to 4.5 hours for selected people. It is never used for a stroke caused by bleeding in the brain, which it would make worse. For a heart attack, it is used for the type in which an artery is completely blocked, called an ST-elevation myocardial infarction (STEMI) after a pattern on an electrocardiogram (ECG), the standard heart-rhythm tracing. Opening the artery with a catheter and stent (percutaneous coronary intervention, or PCI) is preferred when a hospital that can do it is reachable quickly; clot-dissolving medicine is the option when it is not. In a heart attack with a low risk of death or heart failure, the risk of stroke from treatment may outweigh the benefit. For a pulmonary embolism, it is reserved mainly for a large clot in the lungs, especially one causing dangerously low blood pressure. Most other clots in the lungs are treated with anticoagulants (blood thinners). Less often, the drug is delivered through a catheter straight into a large clot in a leg vein (deep vein thrombosis) for carefully selected people, and a small dose of alteplase (Cathflo Activase) is used to clear a blocked central IV line. Some situations rule treatment out because the bleeding risk is too high: active internal bleeding, bleeding in the brain, brain or spine surgery or a serious head injury in the past 3 months, certain brain abnormalities such as an aneurysm, a bleeding disorder, or severe high blood pressure that cannot be controlled. Recent major surgery, recent stomach, bowel or urinary bleeding, pregnancy, older age and current use of a blood thinner such as warfarin all raise the risk and are weighed case by case.

What It Involves

Treatment happens in a hospital, and the clock starts with the first symptom, not with arrival. Ideally the medicine is started within about 30 minutes of reaching the hospital. Because the benefit depends so heavily on time, calling 911 at the first signs of a possible stroke or heart attack is what keeps this treatment possible. For a stroke, the team establishes when symptoms began or when the person was last known to be well, examines strength, speech and vision, and does a brain scan, usually a computed tomography (CT) scan, to rule out bleeding. Blood pressure is brought down to a safe level and kept under control during and after treatment. If the person has not recently taken a blood thinner, treatment can start before clotting test results come back. Alteplase is given through an IV as a small first injection followed by a one-hour infusion; tenecteplase is a single injection given over about 5 seconds. Both doses are based on body weight. Some people with a blockage in a large brain artery also have the clot removed with a catheter (thrombectomy), and for others that procedure is the alternative when clot-dissolving medicine is too risky. For a heart attack, the decision rests on symptoms and the ECG, and a catheter procedure on the heart arteries may follow. For a large pulmonary embolism, alteplase is infused over 2 hours. Catheter-directed treatment for a leg or lung clot is done by an interventional specialist who guides a thin tube to the clot and releases the drug there. Afterward, people are watched closely for bleeding, with frequent checks of blood pressure, alertness, strength and speech. Staff avoid unnecessary needle sticks and injections into muscle. The stroke trials behind these drugs held aspirin and other blood thinners for the first 24 hours, and the team decides when to start them.

What to Expect

Response varies, and the benefit is often less visible at the bedside than people expect. In the original stroke trials, alteplase did not produce more improvement at 24 hours than placebo; its benefit showed up as a better chance of recovering with little or no disability three months later. Some people improve quickly, while others recover gradually or less than hoped, and the treatment shifts the odds rather than guaranteeing a result. Minor bleeding is common, such as oozing where the IV went in, bruising, bleeding gums or nosebleeds. Tell the nurse right away about any new or heavier bleeding, any sudden worsening of symptoms such as weakness, speech or alertness, or swelling of the lips, tongue or throat. That swelling (angioedema) can appear during or up to 2 hours after an alteplase infusion and is more likely in people who take an ACE inhibitor, a common type of blood pressure medicine. Thrombolysis is one step in care rather than the whole treatment. After a stroke, tests look for the cause and rehabilitation helps people regain lost skills. After a heart attack, further procedures may be needed. After a pulmonary embolism, blood thinners continue. Bleeding risk does not end when the infusion stops: it can occur a day or more later, especially once blood thinners are started.

What the Evidence Says

Stroke has the strongest evidence. In the placebo-controlled trials that led to alteplase's approval, people treated within 3 hours were more likely to recover with minimal or no disability at three months: at least 11 more people out of every 100 treated, depending on the measure used. Bleeding in the brain was more common, yet deaths and severe disability at 90 days did not increase. A large review of thrombolysis trials found that, overall, treatment raised early deaths from brain bleeding, but treatment within 3 hours gave the largest benefit without increasing deaths. European stroke guidelines rate the evidence for treatment up to 4.5 hours as high quality. Tenecteplase has been compared directly with alteplase. In a trial of about 1,150 people treated within 3 hours, about 37 in 100 in each group recovered with minimal or no disability, and rates of brain bleeding were similar. Its practical advantage is a single injection instead of an hour-long infusion. For heart attack, clot-dissolving medicine reduces the risk of death, but a catheter procedure is preferred when it can be done quickly. For pulmonary embolism, guidelines strongly recommend it when a clot is causing a dangerous drop in blood pressure. Across trials of serious lung clots, it may reduce deaths and repeat clots, but that evidence is low certainty and weakens in people whose blood pressure was stable, while the increase in major bleeding (roughly three times the odds) is better established. For large leg vein clots, adding thrombolysis to blood thinners reduced long-term leg pain, swelling and skin damage (post-thrombotic syndrome) by about a third, with a small increase in bleeding, in carefully selected people.

Risks & Considerations

Bleeding is the main risk, and it can be life-threatening. It can happen anywhere in the body, but bleeding in the brain is the most serious because it can cause lasting disability or death. In the trial comparing the two stroke drugs, about 3 in 100 people had a brain bleed that worsened their condition, at similar rates with either drug. In treatment for lung clots, major bleeding was roughly three times as likely as with blood thinners alone. Allergic-type reactions are uncommon. The risk is higher in older people, with high blood pressure, after recent surgery, injury or internal bleeding, and in people already taking blood thinners. That is why the team asks quickly about medicines, recent procedures and when symptoms began; a family member who knows these details can help when the patient cannot answer. The decision usually has to be made fast, often with incomplete information, and the balance shifts with time: in stroke, benefit falls the longer treatment is delayed, and in a low-risk heart attack the stroke risk can outweigh the gain. Not every hospital offers stroke thrombolysis, because it requires the ability to manage brain bleeding promptly, and transfer or a catheter procedure may be the better route.

Questions to Ask Your Doctor

  1. 1.Why was thrombolytic therapy recommended or not recommended in my case, and how did it compare with a catheter procedure?
  2. 2.Which of my medicines or health conditions would affect whether I could receive clot-dissolving treatment in a future emergency?
  3. 3.What signs of bleeding should I watch for in the coming days, especially once I start blood thinners?
  4. 4.What tests and treatment will I need to find the cause of this clot and lower the chance of another one?

Last reviewed • Oct 2026

Educational content, not medical advice.